Association of Frailty Index with Clinical Benign Prostatic Hyperplasia Progression and Serious Adverse Events: The MTOPS Trial

    December 2021 in “ Innovation in aging ”
    Sandra Shi, Brianne Olivieri‐Mui, Ellen P. McCarthy, Dae Hyun Kim
    Image of study
    TLDR Frailer men have a higher risk of worsening prostate problems and serious health events needing hospital care.
    In a study involving 3,047 men aged 50-89 years from the Medical Therapy of Prostatic Symptoms Study, researchers found that frailty is independently associated with a higher risk of clinical benign prostatic hyperplasia (BPH) progression and serious adverse events (SAE) requiring hospitalization. Participants were categorized based on a frailty index as fit, less fit, or frail. Over a mean follow-up of 4.5 years, the incidence rate of clinical BPH progression was 2.2 per 100 person-years (p-y) for fit men, 3.0 per 100 p-y for less fit men, and 4.1 per 100 p-y for frail men. Additionally, frail men randomized to combination therapy had a SAE incidence rate of 12.7 per 100 p-y compared to 3.4 per 100 p-y for fit men. The study suggests that treatment decisions for BPH in frail men should carefully weigh the benefits and risks.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 145 results
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 1 year ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

      community How is dht not beneficial to you?

      in Finasteride/Dutasteride  109 upvotes 1 week ago
      DHT is important for sexual function and mood, but finasteride and dutasteride can reduce DHT, causing side effects like reduced libido and erectile dysfunction. These treatments are effective for hair loss, but their impact on DHT leads to debate.

      community risks with finasteride and dutasteride

      in Research/Science  139 upvotes 7 months ago
      Finasteride and dutasteride have potential risks, including post-finasteride syndrome, but are commonly used for hair loss. RU58841, minoxidil, and needling are suggested as alternatives, though all treatments carry risks.

      community Wtf have we been doing for the last 30 years

      in Treatment  548 upvotes 1 year ago
      Hair loss treatments like finasteride, minoxidil, and dutasteride work but have side effects. A permanent cure is still not available due to the complexity of hair loss and limited investment.

    Related Research

    1 / 1 results